The landscape of AI in healthcare is rapidly evolving, demanding a clear understanding of regulatory pathways for both innovators and investors. A critical question for any AI health company today is how to effectively leverage Real-World Evidence (RWE) in their FDA regulatory submissions. For those operating without a defined SaMD pathway, the risks of rising enforcement and health-plan exclusion are becoming increasingly palpable. The companies that navigate this complex terrain successfully often do so by integrating RWE strategically, building robust regulatory strategies from inception.
The Strategic Integration of RWE: Lessons from Market Leaders
Several pioneering companies illustrate the power of RWE in securing regulatory approvals and establishing market dominance. Flatiron Health, for instance, built its entire business model around the collection and strategic application of RWE for FDA submissions, culminating in its acquisition by Roche for $2.1 billion USD. This demonstrates a clear valuation premium for companies that can effectively harness RWE to de-risk their regulatory journey and prove clinical utility.
Other notable players are also demonstrating the utility of RWE. Tempus AI, a leader in precision medicine, leverages vast datasets to inform its AI algorithms, which are then supported by RWE in regulatory filings. Tempus AI has recently secured FDA approval for a tumor-only indication for its xT CDx next-generation sequencing platform, making it the first laboratory to hold FDA companion diagnostic approval for both tumor-only and tumor-normal comprehensive genomic profiling. Additionally, Tempus received 510(k) clearance for its RNA-based Tempus xR IVD device in September 2025 and for its Tempus ECG-AF device, an AI-based algorithm to identify patients at increased risk of atrial fibrillation/flutter, in July 2024. This dual approach, robust AI development coupled with real-world validation, strengthens their case for efficacy and safety. Similarly, HeartFlow, with its AI-powered FFRct analysis, has successfully navigated the regulatory landscape, using extensive clinical data and RWE to support its De Novo classification and subsequent reimbursement. HeartFlow also received a new FDA 510(k) clearance in September 2025 for its Next Gen Heartflow Plaque Analysis algorithm, which offers improved plaque detection, and has secured nationwide coverage from Cigna and UnitedHealthcare for this platform. Their approach highlights how novel AI solutions, even without a direct predicate, can achieve regulatory success by demonstrating clear clinical benefit through RWE.
Viz.ai provides another compelling example, utilizing AI to detect suspected strokes and pulmonary embolisms. Their regulatory clearances, including multiple 510(k)s, are underpinned by strong RWE demonstrating improved patient outcomes and workflow efficiencies. Recent clearances include Viz Subdural Plus (June 2025) for quantifying subdural hemorrhage, Viz ICH Plus (February 2024) for quantifying intracerebral hemorrhage, and Viz AAA (March 2023) for detecting suspected abdominal aortic aneurysm. Paige AI, focusing on AI-powered pathology, has also made significant strides, leveraging large-scale pathological image data and RWE to gain FDA clearances for its diagnostic tools. Paige’s FullFocus™ digital pathology image viewer received FDA 510(k) clearance in January 2025 for use with additional scanner systems. Furthermore, Paige Prostate Detect received the first FDA De Novo marketing authorization for AI in pathology in September 2021, and the company received Breakthrough Device designations in 2019 for AI in cancer diagnosis and in 2025 for PanCancer Detect. These companies collectively underscore a fundamental truth: the ability to generate, analyze, and present high-quality RWE is not merely a scientific exercise, but a strategic imperative for AI health companies seeking regulatory success and commercial viability.
Regulatory Frameworks and the Power of Real-World Evidence
The FDA, particularly through its Center for Devices and Radiological Health (CDRH), has increasingly recognized the value of RWE. Under the leadership of figures like Bakul Patel, who championed the FDA’s work on digital health, and former Commissioner Scott Gottlieb, there has been a growing emphasis on leveraging RWE to streamline regulatory processes for innovative medical technologies, including AI. The FDA SaMD Framework provides a clear pathway for software-based medical devices, and RWE plays a crucial role in substantiating claims for both initial clearances and post-market surveillance. FDA guidance on SaMD framework and RWE
For AI health tools, the regulatory journey often involves navigating pathways such as the FDA 510(k) for devices substantially equivalent to an existing predicate, or the FDA De Novo classification for novel, low-to-moderate-risk devices without a predicate. In both scenarios, compelling RWE can significantly strengthen a submission. Furthermore, adherence to standards like 21 CFR Part 11, which governs electronic records and electronic signatures, ensures the integrity and trustworthiness of the digital data comprising RWE, a critical component for regulatory acceptance.
The strategic use of RWE allows companies to demonstrate the safety and effectiveness of their AI tools in real-world clinical settings, beyond the controlled environment of traditional clinical trials. This is particularly vital for AI, which often learns and adapts over time. The ability to continuously monitor performance and demonstrate real-world impact through RWE can be a differentiator, not just for regulatory approval, but also for securing payer coverage and clinician adoption.
The Cost of Neglect: Rising Enforcement and Exclusion Risks
For AI health companies that fail to define a clear FDA SaMD pathway and integrate RWE strategically, the risks are escalating. The FDA’s enforcement capabilities are growing, and the agency is increasingly scrutinizing AI health tools that operate in the medical domain without proper regulatory oversight. Operating in a grey area, or relying solely on a “clinical decision support” label to avoid regulation, is becoming a perilous strategy. The distinction between clinical decision support and a regulated diagnostic or therapeutic device is becoming clearer, and companies that cross that line without appropriate clearances face potential enforcement actions, including product recalls, warning letters, and significant fines.
Beyond regulatory enforcement, the commercial landscape is also becoming less forgiving. Health plans and payers are increasingly demanding robust clinical evidence, often including RWE, to justify reimbursement for AI health tools. Without FDA clearance via a defined SaMD pathway, and without compelling RWE to demonstrate clinical utility and cost-effectiveness, securing favorable reimbursement becomes an uphill battle. This means that even if a product technically avoids regulatory action, it may struggle to achieve widespread adoption and financial viability due to lack of payer coverage. Investors, particularly VCs, are increasingly performing due diligence on these regulatory and reimbursement pathways, recognizing that a strong regulatory strategy, supported by RWE, is a key de-risking factor. Payer guidelines for AI health tool reimbursement
The market is rapidly bifurcating: on one side are companies that have embraced the FDA SaMD framework, strategically leveraged RWE, and secured appropriate clearances; on the other are those who have not. The latter group faces not only regulatory jeopardy but also significant hurdles in achieving commercial scale and attracting further investment. The era of “move fast and break things” without regulatory consideration is definitively over in AI health. Analysis of FDA enforcement actions against unregulated health tech
Conclusion
The trajectory of leading AI health companies like Flatiron Health, Tempus AI, HeartFlow, Viz.ai, and Paige AI unequivocally demonstrates that a well-defined FDA SaMD pathway, critically bolstered by Real-World Evidence, is not merely a compliance burden but a strategic asset. For clinicians, this means greater assurance in the safety and efficacy of the AI tools they integrate into practice. For investors and VCs, it signals a de-risked investment with a clearer path to market adoption and reimbursement. Companies that fail to proactively integrate RWE into their regulatory strategy risk not only enforcement actions from the FDA but also significant challenges in securing health plan coverage, ultimately hindering their ability to deliver on their promise of transforming healthcare. The message is clear: regulatory foresight and the strategic use of RWE are paramount for success in the regulated AI health ecosystem.
Frequently Asked Questions
Why is Real-World Evidence (RWE) crucial for AI health companies seeking FDA approval?
RWE is crucial because it helps de-risk the regulatory journey and prove clinical utility, especially for AI health solutions. It allows companies to demonstrate the safety and effectiveness of their AI tools in real-world clinical settings, which is vital for both initial clearances and post-market surveillance. Companies that strategically integrate RWE often achieve regulatory success and commercial viability.
How have market leaders successfully leveraged RWE in their FDA submissions?
Market leaders like Flatiron Health, Tempus AI, HeartFlow, Viz.ai, and Paige AI have leveraged RWE to secure regulatory approvals and establish market dominance. They built business models around RWE collection, used vast datasets to inform AI algorithms supported by RWE in filings, and used extensive clinical data and RWE to support novel classifications and subsequent reimbursement. This dual approach of robust AI development coupled with real-world validation strengthens their case for efficacy and safety.
What specific FDA pathways are relevant for AI health tools and how does RWE fit in?
AI health tools often navigate FDA pathways such as the 510(k) for devices substantially equivalent to a predicate, or the De Novo classification for novel, low-to-moderate-risk devices without a predicate. In both scenarios, compelling RWE significantly strengthens a submission by demonstrating safety and effectiveness in real-world clinical settings. RWE also plays a crucial role in substantiating claims for initial clearances and post-market surveillance within the FDA SaMD Framework.
Beyond FDA approval, what other benefits does strategic RWE integration offer?
Beyond FDA approval, strategic RWE integration offers benefits such as securing payer coverage and clinician adoption. The ability to continuously monitor performance and demonstrate real-world impact through RWE can be a key differentiator. This helps ensure commercial viability and broader market acceptance for AI health solutions.
